5/2/2019 4:27:22 PM
Viking Therapeutics Q1 Loss/share $0.07 Vs. Loss $0.10 Year Ago
4/11/2019 7:05:17 AM
Viking Therapeutics Presents New Data From Phase 2 Study Of VK2809 In Patients With NAFLD And Elevated LDL-Cholesterol
4/4/2019 7:32:38 AM
Viking Therapeutics To Present New Data From Phase 2 Study Of VK2809 In Patients With NAFLD And Elevated LDL-Cholesterol
3/29/2019 7:45:58 AM
William Blair Reiterates Viking Therapeutics, Inc. (VKTX) At Outperform
3/14/2019 8:44:35 AM
William Blair Reiterates Viking Therapeutics, Inc. (VKTX) At Outperform
3/13/2019 4:09:12 PM
Viking Therapeutics Q4 Loss/share $0.07 Vs. Loss $0.14 Year Ago
11/12/2018 7:39:14 PM
Viking Presents Results From Phase 2 Study Of VK2809 In Patients With NAFLD
10/8/2018 7:09:21 AM
Viking Therapeutics Says Data From In Vivo Study Of VK2809 Presented At Oral Plenary Session At ATA
10/1/2018 7:51:04 AM
William Blair Reiterates Viking Therapeutics, Inc. (VKTX) At Market Perform
10/1/2018 7:05:22 AM
Viking Therapeutics Presents Results From Phase 2 Study Of VK5211; Study Achieves Primary Endpoint
9/20/2018 8:53:59 PM
Viking Therapeutics Prices Public Offering Of 9.50 Mln Shares At $18.50/shr
9/19/2018 4:31:57 PM
Viking Therapeutics Announces Proposed Public Offering Of Common Stock
9/18/2018 7:07:27 AM
Viking Therapeutics Announces Positive Top-Line Results From Phase 2 Study Of VK2809
8/10/2018 7:55:42 AM
William Blair Is Raising Viking Therapeutics, Inc. (VKTX) FY20 Estimate To -0.79 From -0.89